Discrepancy between patient expectations and experiences with anti-fibrotic drugs in idiopathic pulmonary fibrosis

被引：2
|
作者：
Moor, Catharina
Kimman, Merel L.
van Manen, Mirjam J. G.
Dirksen, Carmen D.
Wijsenbeek, Marlies S.
Van Jaarsveld, F. Xana
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2017年 / 50卷
关键词：
D O I：
10.1183/1393003.congress-2017.PA4884
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA4884
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Anti-Fibrotic Therapy and Patient Reported Outcomes in Idiopathic Pulmonary Fibrosis
    Kay, S.
    White, E. S.
    Sheth, J. S.
    Flaherty, C.
    Getty, C.
    Holtze, C.
    Wang, B.
    Salisbury, M.
    Belloli, E.
    Flaherty, K. R.
    Murray, S.
    Xia, M.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [2] Effects of Anti-Fibrotic Drugs on Transcriptome of Peripheral Blood Mononuclear Cells in Idiopathic Pulmonary Fibrosis
    Ishii, Daisuke
    Kawasaki, Takeshi
    Sato, Hironori
    Tatsumi, Koichiro
    Imamoto, Takuro
    Yoshioka, Keiichiro
    Abe, Mitsuhiro
    Hasegawa, Yoshinori
    Ohara, Osamu
    Suzuki, Takuji
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [3] The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis
    Matsumoto, Yoko
    Furukawa, Ryutaro
    Ohara, Sayaka
    Usui, Kazuhiro
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [4] Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications
    Nair, Girish B.
    Matela, Ajsza
    Kurbanov, Daniel
    Raghu, Ganesh
    [J]. EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (06) : 699 - 711
  • [5] Anti-fibrotic role of inhaled interferon-γ in idiopathic pulmonary fibrosis
    Hasaneen, Nadia
    Tuong Vu
    Fusiak, Timothy
    Foda, Hussein
    Condos, Rany
    Smaldone, Gerald
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [6] DISEASE PROGRESSION IN IDIOPATHIC PULMONARY FIBROSIS UNDER ANTI-FIBROTIC TREATMENT
    Cilli, Aykut
    Uzer, Fatih
    [J]. SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2023, 40 (03)
  • [7] Factors Affecting The Selection Of Anti-Fibrotic Therapy For Idiopathic Pulmonary Fibrosis
    Kaur, R.
    King, C.
    Brown, A.
    Ahmad, S.
    Shlobin, O. A.
    Weir, N.
    Nathan, S. D.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [8] A HUMAN MODEL OF LUNG FIBROSIS FOR THE ASSESSMENT OF ANTI-FIBROTIC STRATEGIES IN IDIOPATHIC PULMONARY FIBROSIS
    Roach, K. M.
    Tongue, P.
    Castells, E.
    Elliot, G.
    Marshall, H.
    Richardson, M.
    Mason, S.
    Chachi, L.
    Bradding, P.
    [J]. THORAX, 2019, 74 : A56 - A57
  • [9] The Interaction Between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs
    Shen, Hao
    Zhang, Nu
    Liu, Yuqing
    Yang, Xuerong
    He, Yuanyuan
    Li, Qi
    Shen, Xiaoyan
    Zhu, Yulian
    Yang, Yong
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [10] Real-life survival of idiopathic pulmonary fibrosis with anti-fibrotic medication
    Bleinc, Alexandre
    Blin, Timothee
    Legue, Sylvie
    Mankikian, Julie
    Plantier, Laurent
    Marchand-Adam, Sylvain
    [J]. REVUE DES MALADIES RESPIRATOIRES, 2023, 40 (05) : 371 - 381
12345